EP4344703 - METHODS OF USING PYRUVATE KINASE ACTIVATORS [Right-click to bookmark this link] | Status | The application has been published Status updated on 01.03.2024 Database last updated on 24.08.2024 | Most recent event Tooltip | 28.06.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Agios Pharmaceuticals, Inc. 88 Sidney Street Cambridge, MA 02139 / US | [2024/14] | Inventor(s) | 01 /
AGRESTA, Samuel, V. Lexington, MA / US | 02 /
CHEN, Yue Quincy, MA / US | 03 /
COHEN, Marvin Barry Newtown, PA / US | 04 /
DANG, Leonard Luan C. Boston, MA / US | 05 /
KUNG, Charles Arlington, MA / US | 06 /
MERICA, Elizabeth A. Boston, MA / US | 07 /
SILVER, Bruce Alan Dunkirk, MD / US | 08 /
YANG, Hua Acton, MA / US | [2024/14] | Representative(s) | Maiwald GmbH Elisenhof Elisenstraße 3 80335 München / DE | [2024/14] | Application number, filing date | 23196616.9 | 10.06.2016 | [2024/14] | Priority number, date | US201562174216P | 11.06.2015 Original published format: US 201562174216 P | [2024/14] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP4344703 | Date: | 03.04.2024 | Language: | EN | [2024/14] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 05.03.2024 | Classification | IPC: | A61K31/4709, A61K31/496, C07D215/36, A61P7/06, A61K9/00 | [2024/14] | CPC: |
A61K31/496 (EP,US);
A61P7/06 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2024/14] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | MD | Not yet paid | Title | German: | VERFAHREN ZUR VERWENDUNG VON PYRUVATKINASEAKTIVATOREN | [2024/14] | English: | METHODS OF USING PYRUVATE KINASE ACTIVATORS | [2024/14] | French: | PROCÉDÉS D'UTILISATION D'ACTIVATEURS DE LA PYRUVATE KINASE | [2024/14] | Parent application(s) Tooltip | EP16808374.9 / EP3307271 | Fees paid | Renewal fee | 11.09.2023 | Renewal fee patent year 03 | 11.09.2023 | Renewal fee patent year 04 | 11.09.2023 | Renewal fee patent year 05 | 11.09.2023 | Renewal fee patent year 06 | 11.09.2023 | Renewal fee patent year 07 | 11.09.2023 | Renewal fee patent year 08 | 27.06.2024 | Renewal fee patent year 09 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y]WO2012151451 (AGIOS PHARMACEUTICALS INC [US], et al) [Y] 1-12 * page 1, line 5 - page 3, paragraph 1 * * page 4, paragraph 3 - page 4, paragraph 1 * * page 23, paragraph last - page 25, paragraph first * * claims 1-30 * * figure 1/79 *; | [Y]US2014155408 (SU SHIN-SAN MICHAEL [US]) [Y] 1-12 * page 2, paragraph 9 * * page 2, paragraph 14 - paragraph 16 * * page 44, paragraph 194 *; | [A]US2014323467 (SALITURO FRANCESCO G [US], et al) [A] 1-12 * page 1, paragraph 24 * * page 2, paragraph 30 * * page 8, paragraph 156 * * page 16, paragraph 235 * * page 17, paragraph 240 * * page 229, paragraph 1324 *; | [Y] - KUNG CHARLES ET AL, "AG-348 Activation of Pyruvate Kinase in Vivo Enhances Red Cell Glycolysis in Mice", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (20141201), XP002787328 [Y] 1-12 * abstract * | [Y] - YANG HUA ET AL, "Phase I Single (SAD) and Multiple Ascending Dose (MAD) Studies of the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of AG-348, a First-in-Class Allosteric Activator of Pyruvate Kinase-R, in Healthy Subjects", BIOSIS, BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US, (201412), Database accession no. PREV201500280858, XP002787329 [Y] 1-12 * abstract * | [A] - DIMITRIOS ANASTASIOU, "Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis Correspondence: performed in vivo pharmacology and ADME studies wrote the paper with significant input from Y", NAT CHEM BIOL., (20121001), vol. 8, no. 10, pages 839 - 847, XP055333200 [A] 1-12 * the whole document * | by applicant | US8785450 | - ZANELLA, A. et al., Br JHaematol, (20050000), vol. 129, no. 6, pages 839 - 46 | - KEDAR, P. et al., Clin Genet, (20090000), vol. 75, no. 2, pages 157 - 62 | - AIZAWA, S et al., Exp Hematol, (20050000), vol. 33, no. 11, pages 1292 - 8 | - BEUTLER, E., Blood, (20000000), vol. 95, no. 11, pages 3585 - 8 | - TAVAZZI, D et al., PediatrAnn, (20080000), vol. 37, no. 5, pages 303 - 10 | - KANNO, H et al., Proc Natl Acad Sci U SA, (19910000), vol. 88, no. 18, pages 8218 - 21 | - ZANELLA, A. et al., Br J Haematol, (20050000), vol. 130, no. 1, pages 11 - 25 | - PISSARD, S et al., JHaematol, (20060000), vol. 133, no. 6, pages 683 - 9 | - Am J Gastroenterol, (19870000), vol. 82, no. 12, page 1283 | - PARKINSON'S, J. Neurol, Neurosurg, and Psychiatry, (19760000), vol. 39, page 952 |